Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs

Valentina Mercurio, Flora Pirozzi, Edoardo Lazzarini, Giancarlo Marone, Paola Rizzo, Giulio Agnetti, Carlo G. Tocchetti, Alessandra Ghigo, Pietro Ameri

Research output: Contribution to journalReview article

Abstract

Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.

LanguageEnglish (US)
Pages449-458
Number of pages10
JournalJournal of Cardiac Failure
Volume22
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Heart Failure
Pharmaceutical Preparations
Anthracyclines
Second Primary Neoplasms
Antineoplastic Agents
Stem Cells
Neuregulin-1
Platelet-Derived Growth Factor Receptors
Vascular Endothelial Growth Factor Receptor
Cardiotoxicity
Platelet-Derived Growth Factor
Cardiac Myocytes
Vascular Endothelial Growth Factor A
DNA Damage
Oxidative Stress
Therapeutics
Population
Neoplasms

Keywords

  • anthracyclines
  • antineoplastic drugs-induced cardiotoxicity
  • Heart failure
  • receptor tyrosine kinase

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mercurio, V., Pirozzi, F., Lazzarini, E., Marone, G., Rizzo, P., Agnetti, G., ... Ameri, P. (2016). Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. Journal of Cardiac Failure, 22(6), 449-458. DOI: 10.1016/j.cardfail.2016.04.008

Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. / Mercurio, Valentina; Pirozzi, Flora; Lazzarini, Edoardo; Marone, Giancarlo; Rizzo, Paola; Agnetti, Giulio; Tocchetti, Carlo G.; Ghigo, Alessandra; Ameri, Pietro.

In: Journal of Cardiac Failure, Vol. 22, No. 6, 01.06.2016, p. 449-458.

Research output: Contribution to journalReview article

Mercurio, V, Pirozzi, F, Lazzarini, E, Marone, G, Rizzo, P, Agnetti, G, Tocchetti, CG, Ghigo, A & Ameri, P 2016, 'Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs' Journal of Cardiac Failure, vol 22, no. 6, pp. 449-458. DOI: 10.1016/j.cardfail.2016.04.008
Mercurio V, Pirozzi F, Lazzarini E, Marone G, Rizzo P, Agnetti G et al. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. Journal of Cardiac Failure. 2016 Jun 1;22(6):449-458. Available from, DOI: 10.1016/j.cardfail.2016.04.008
Mercurio, Valentina ; Pirozzi, Flora ; Lazzarini, Edoardo ; Marone, Giancarlo ; Rizzo, Paola ; Agnetti, Giulio ; Tocchetti, Carlo G. ; Ghigo, Alessandra ; Ameri, Pietro. / Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs. In: Journal of Cardiac Failure. 2016 ; Vol. 22, No. 6. pp. 449-458
@article{f1af227c17cf43ee86978bbd6c56cfcf,
title = "Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs",
abstract = "Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.",
keywords = "anthracyclines, antineoplastic drugs-induced cardiotoxicity, Heart failure, receptor tyrosine kinase",
author = "Valentina Mercurio and Flora Pirozzi and Edoardo Lazzarini and Giancarlo Marone and Paola Rizzo and Giulio Agnetti and Tocchetti, {Carlo G.} and Alessandra Ghigo and Pietro Ameri",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.cardfail.2016.04.008",
language = "English (US)",
volume = "22",
pages = "449--458",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "6",

}

TY - JOUR

T1 - Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs

AU - Mercurio,Valentina

AU - Pirozzi,Flora

AU - Lazzarini,Edoardo

AU - Marone,Giancarlo

AU - Rizzo,Paola

AU - Agnetti,Giulio

AU - Tocchetti,Carlo G.

AU - Ghigo,Alessandra

AU - Ameri,Pietro

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.

AB - Heart failure (HF) is a complication of oncological treatments that may have dramatic clinical impact. It may acutely worsen a patient's condition or it may present with delayed onset, even years after treatment, when cancer has been cured or is in stable remission. Several studies have addressed the mechanisms of cancer therapy-related HF and some have led to the definition of disease models that hold valid for other and more common types of HF. Here, we review these models of HF based on the cardiotoxicity of antineoplastic drugs and classify them in cardiomyocyte-intrinsic, paracrine, or potentially secondary to effects on cardiac progenitor cells. The first group includes HF resulting from the combination of oxidative stress, mitochondrial dysfunction, and activation of the DNA damage response, which is typically caused by anthracyclines, and HF resulting from deranged myocardial energetics, such as that triggered by anthracyclines and sunitinib. Blockade of the neuregulin-1/ErbB4/ErbB2, vascular endothelial growth factor/vascular endothelial growth factor receptor and platelet-derived growth factor /platelet-derived growth factor receptor pathways by trastuzumab, sorafenib and sunitinib is proposed as paradigm of cancer therapy-related HF associated with alterations of myocardial paracrine pathways. Finally, anthracyclines and trastuzumab are also presented as examples of antitumor agents that induce HF by affecting the cardiac progenitor cell population.

KW - anthracyclines

KW - antineoplastic drugs-induced cardiotoxicity

KW - Heart failure

KW - receptor tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84969240166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969240166&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2016.04.008

DO - 10.1016/j.cardfail.2016.04.008

M3 - Review article

VL - 22

SP - 449

EP - 458

JO - Journal of Cardiac Failure

T2 - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 6

ER -